We are live on
!
Find out more
TCM
Trybe Capital Management Portfolio holdings
AUM
$1.09B
1-Year Est. Return
249.75%
This Fund
S&P 500
This Quarter
Est. Return
-3.5%
1 Year Est. Return
+249.75%
3 Year Est. Return
+680.91%
5 Year Est. Return
+833.26%
10 Year Est. Return
–
AUM
$104M
AUM Growth
-$43.3M
(-29%)
Cap. Flow
-$38.7M
Cap. Flow
% of AUM
-37.2%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
13
New
1
Increased
–
Reduced
9
Closed
3
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ginkgo Bioworks
DNA
|
+$3.29M |
| 2 |
Apple
AAPL
|
+$1.88M |
| 3 |
NVIDIA
NVDA
|
+$791K |
| 4 |
ServiceNow
NOW
|
+$667K |
| 5 |
Microsoft
MSFT
|
+$647K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 59.24% |
| 2 | Communication Services | 14.28% |
| 3 | Consumer Discretionary | 8.37% |
| 4 | Healthcare | 0% |
Similar funds
AA
LEA
RA
AAIM
CFFNO
IF
APC
SAM
Trybe Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, Trybe Capital Management held 13 positions worth $104M, down 29% from $147M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Trybe Capital Management withdrew a net $38.7M in Q4 2022, closing 3 positions and reducing 9 holdings. Its most notable exit was Ginkgo Bioworks, an estimated $3.29M position sold in full.
By sector, the portfolio is most concentrated in Technology at 59% of assets, up from 45% a quarter earlier, followed by Communication Services and Consumer Discretionary.
- Trybe Capital Management's biggest Q4 2022 reduction was Apple, cutting an estimated $1.88M.
- Trybe Capital Management fully exited Ginkgo Bioworks in Q4 2022, selling an estimated $3.29M.
- Trybe Capital Management's ten largest holdings make up 100% of its $104M portfolio in Q4 2022.
- Trybe Capital Management opened 1 new position and closed 3 in Q4 2022.
- Trybe Capital Management's portfolio value fell 29% quarter-over-quarter to $104M.
Based on Trybe Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.